J. Kulkarni
Molecular Biology · Nature Nanotechnology · 2019–2022
A researcher in the Science corpus: 4 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 71 citations into it
- Biomedical Engineering — 9 citations into it
- Biomaterials — 7 citations into it
Whom J. Kulkarni trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from J. Kulkarni's perspective
Ordered by how strongly the researchers J. Kulkarni trusts endorse each paper. Same corpus, a different order for every researcher.
- A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates. (Molecular Therapy)
- Pharmacokinetics and biodistribution of nanoparticles. (Molecular Pharmaceutics)
- mRNA-based therapeutics — developing a new class of drugs (Nature reviews. Drug discovery)
- Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling (Nature Biotechnology)
- Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation
- The many pathways of RNA degradation. (Cell)
- Freeze-drying of nanoparticles: formulation, process and storage considerations. (Advanced Drug Delivery Reviews)
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine (New England Journal of Medicine)
- Pharmacokinetics of Pegylated Liposomal Doxorubicin (Clinical Pharmacokinetics)
- Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms. (Molecular Therapy)
Their papers
- The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs (2019) — 1,342 citations
- mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability (2021) — 1,255 citations
- The role of lipid components in lipid nanoparticles for vaccines and gene therapy (2022) — 966 citations
- The current landscape of nucleic acid therapeutics (2021) — 1,072 citations